B. Riley analyst Mayank Mamtani downgraded Centessa (CNTA) to Neutral from Buy with a $45 price target after Eli Lilly (LLY) announced an agreement to acquire the company for $38 per share in cash plus a non-transferable CVR worth up to $9 per share.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTA:
- Morning Movers: Marvell jumps following Nvidia investment, AI factory pact
- Video: Deals in food and pharmaceuticals headline busy morning of M&A
- Eli Lilly (LLY) Enters Sleep Disorder Business with $7.8 Billion Acquisition of Centessa
- Centessa downgraded to Hold from Buy at Needham
- Centessa downgraded to Equal Weight from Overweight at Stephens